Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa
Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa
复制标题
DOI：
10.4065/mcp.2010.0674
复制
发表时间：
2011-03-01
影响因子：
8.9
通讯作者：
Kanafani, Zeina A.
中科院分区：
文献类型：
--
作者：
Kanj, Souha S.;Kanafani, Zeina A.
革兰氏阴性病原菌的耐药性发展是渐进的和无情的。引起特别关注的病原体包括产超广谱β-内酰胺酶的肠杆菌科细菌、耐碳青霉烯类的肠杆菌科细菌和耐多药的铜绿假单胞菌。用于治疗这些病原体的经典药物已经过时了。在为数不多的几种新药中，许多已经成为细菌耐药机制的靶点。这篇综述描述了目前治疗这些耐药微生物引起的感染的方法，并阐述了可用的治疗方案。
The development of antimicrobial resistance among gram-negative pathogens has been progressive and relentless. Pathogens of particular concern include extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruglnosa. Classic agents used to treat these pathogens have become outdated. Of the few new drugs available, many have already become targets for bacterial mechanisms of resistance. This review describes the current approach to infections due to these resistant organisms and elaborates on the available treatment options.